ArticleThe Lancet. Microbe2022

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.

Mohammad Bosaeed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.